載入中
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
前收盤價
US$0.871
−US$0.049 · -5.33%
盤中時間採用ET。市場資料可能有所延遲。
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
日內區間
目前US$0.871
52週區間
目前US$0.871
盤中時間採用ET。市場資料可能有所延遲。
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
日內區間
目前US$0.871
52週區間
目前US$0.871
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 10萬 USD | 40萬 USD | 22.5萬 USD | — | 188.4萬 USD |
| 銷貨成本 | — | — | — | — | 379.1萬 USD |
| 毛利 | 10萬 USD | 40萬 USD | 22.5萬 USD | — | −190.7萬 USD |
| 研究與開發 | 1964.3萬 USD | 831.2萬 USD | 518.5萬 USD | 1032.7萬 USD | 982.7萬 USD |
| 銷售、一般及管理費用 | 1059.5萬 USD | 1069萬 USD | 1167.4萬 USD | 1845.1萬 USD | 1796.3萬 USD |
| 營業費用 | 3524.1萬 USD | 1900.2萬 USD | 1685.9萬 USD | 2934.3萬 USD | 2779萬 USD |
| 利息收入 | 215萬 USD | 43.7萬 USD | 36.3萬 USD | 21.3萬 USD | 17.7萬 USD |
| 利息支出 | 5.3萬 USD | 21.2萬 USD | 17.2萬 USD | 8.3萬 USD | 141.2萬 USD |
| 折舊和攤銷 | 103萬 USD | 112.6萬 USD | 125萬 USD | 138萬 USD | 379.1萬 USD |
| 營業利益 | −3514.1萬 USD | −1860.2萬 USD | −1663.4萬 USD | −2934.3萬 USD | −2969.7萬 USD |
| 淨利 | −3304.4萬 USD | −1837.7萬 USD | −2490.7萬 USD | −6501萬 USD | −5039.1萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
